Thailanstatin A manufacturers
- Thailanstatin A
-
- $187.00
-
2026-07-14
- CAS:1426953-21-0
- Purity: 99.31%
- Supply Ability: 10g
|
| | Thailanstatin A Basic information |
| Product Name: | Thailanstatin A | | Synonyms: | 1,6-Dioxaspiro[2.5]octane-5-acetic acid, 7-[(1E,3E)-5-[(2S,3S,5R,6R)-5-[[(2Z,4S)-4-(acetyloxy)-1-oxo-2-penten-1-yl]amino]tetrahydro-3,6-dimethyl-2H-pyran-2-yl]-3-methyl-1,3-pentadien-1-yl]-8-hydroxy-, (3R,5S,7R,8R)-;Thailandstatin A;Thailanstatin A;ADC Payload,natural,Inhibitor,inhibit,SF3b,subunit,antiproliferative,Thailanstatin A,spliceosome,ADC,ADC Cytotoxin,RNA,linker;6-dioxaspiro[2.5]oct-5-yl]acetic acid;2-[(3R,5S,7R,8R)-7-[(1E,3E)-5-[(2S,3S,5R,6R)-5-[(2Z,4S)-4-(acetyloxy)pent-2-enamido]-3,6-dimethyloxan-2-yl]-3-methylpenta-1,3-dien-1-yl]-8-hydroxy-1,6-dioxaspiro[2.5]octan-5-yl]acetic acid;Terance Statin A | | CAS: | 1426953-21-0 | | MF: | C28H41NO9 | | MW: | 535.63 | | EINECS: | | | Product Categories: | ADC | | Mol File: | 1426953-21-0.mol |  |
| | Thailanstatin A Chemical Properties |
| Boiling point | 757.3±60.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | solubility | DMSO : 250 mg/mL (466.74 mM; Need ultrasonic) | | pka | 4.37±0.10(Predicted) | | form | Solid | | color | White to off-white | | InChIKey | GJKQDOMCDFJANR-FUDLAKRJSA-N | | SMILES | O1[C@@]2([C@H](O)[C@@H](/C=C/C(/C)=C/C[C@@H]3O[C@H](C)[C@H](NC(=O)/C=C\[C@@H](OC(C)=O)C)C[C@@H]3C)O[C@H](CC(O)=O)C2)C1 |
| | Thailanstatin A Usage And Synthesis |
| Description | Thailanstatin A, a promising lead compound for drug discovery and development efforts, is derived from Thailandensis burkholderia MSMB43. It reveals low nanomolar to subnanomolar cytotoxicity against a variety of human cancer cell lines. | | Definition | ChEBI: Thailanstatin A is a C-glycosyl compound. | | Mechanism of action | The mechanism of action (MOA) of thailanstatin A is the inhibition of spliceosome assembly. Thailanstatin A binds firmly to the SF3b subunit of the U2 snRNA sub-complex, a crucial component of the spliceosome. Since the spliceosomes of cancer cells are more active and exhibits higher mutation rates than those of normal cells, this sub-cellular component is by far the most well-established anti-tumor target in novel drug discoveries. | | Synthesis | 
Thailanstatin A (1): To a stirred solution of epoxide 6 (4.0 mg, 0.012 mmol, 1.0 equiv) and boronate 5 (5.8 mg, 13 |ìmol, 1.1 equiv) in rigorously degassed (freeze-pump-thaw technique3) 3:1:1 1,4-dioxane/MeCN/H2O (0.64 mL,) at 25C. was added tripotassium phosphate monohydrate (2.8 mg, 0.012 mmol, 1.0 equiv) followed by Pd(dppf)Cl2.CH2Cl2 (0.1 mg, 0.125 |ìmol, 0.025 equiv). After 10 min, the reaction mixture was neutralized with phosphate buffer (NaH2PO4, 1.0 M, 2.5 mL), filtered through a layer of Celite, and rinsed thoroughly with ethyl acetate (20 mL). Then the organic layer was dried with anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was purified by reversed-phase HPLC (C18, |19150 mm, Atlantis, 40ú50% aqueous MeCN containing 0.03% TFA) to afford thailanstatin A (1) (ca. 3.0 mg, 6.0 |ìmol, 52%) as a white foam. |
| | Thailanstatin A Preparation Products And Raw materials |
|